FDA finalizes clinical guidance for psychedelic drugs, easing abuse-study requirements, and sets a Sept. 14 hearing on therapeutic use.
The FDA has finalized clinical guidance for psychedelic drug developers and has scheduled a public hearing on future therapeutic use, adding regulatory momentum to a …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
News and commentary from the psychiatry world
The FDA announced regulatory actions Friday to support development of serotonin-2A agonists and related products, including…
It's a big shift toward supporting psychedelic-based medicines for treatment-resistant depression, PTSD and substance use…
Definium Therapeutics said that its LSD therapy helped patients with major depression in its first Phase 3 trial, bringing the…
SAN FRANCISCO — Psychedelics in mental health treatment is a rapidly changing landscape, but it is important for primary care…
Since President Donald J. Trump’s executive order to increase access to psychedelics and other alternative therapies for mental…
